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Introduction
Transmembrane efflux pumps play an increasing role in
the success of ART. The occurrence of increasing mRNA
levels of the efflux pump proteins P-gp and MRP subtypes
has been associated with ART therapeutics like PIs and
NNRTIs. Moreover, a relation has been suggested of MRP
subtypes and CD4 cell counts. So there is a challenge to
find selective MRP inhibitors which may reduce MRP-
induced drug resistances as well as discussed effects on
CD4 cells. We developed novel nonpeptidic inhibitors of
important MRP subtypes related to both MRP-mediated
resistances as well as reduced cell counts.
Materials and methods
The molecular structures of the various efflux pumps
guided the development of both symmetric and nonsym-
metric inhibitors dedicated to selectively inhibit the rele-
vant MRP-subtypes. Inhibiting properties were evaluated
in exclusively P-gp as well as MRP-overexpressing cell
lines in comparison to nonexpressing parental cell lines
with fluorescent substrates using flow cytometry.
Results
Our inhibitors with allover symmetric substitution pat-
terns are excellent P-gp inhibitors, while a reduction of
those symmetric elements concerning their number
and exact positioning significantly lowers the P-gp
inhibition whereas the MRP1 inhibition is found
mainly increased. So selective inhibitors are demon-
strated to influence the efflux pump type-related anti-
retroviral drug resistance.
Conclusions
The success of ART may be mainly increased by selec-
tive MRP inhibitors which reduce the MRP-related
effects on drug resistance as well as on discussed cell
counts. Structure-guided studies of the efflux pump
inhibition helped to design novel selective inhibitors
with structure-reasoned effects of the nonsymmetric sub-
stitution patterns. So far only nonselective inhibitors have
been used in ART with undesired effects on transporter-
related pharmacokinetics. Selective inhibitors will mean a
progress in ART especially with less limiting side effects.
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